Skip Navigation

Find a Doctor

Find a Researcher

Nicole M Salazar-Austin, M.D., Sc.M.

Nicole M Salazar-Austin, M.D., Sc.M.

Headshot of Nicole M Salazar-Austin
  • Assistant Professor of Pediatrics

Languages: English, Spanish

Expertise

Tuberculosis

Background

Dr. Salazar-Austin completed her undergraduate degree in Biology at the Massachusetts Institute of Technology and her medical degree from Harvard Medical School. She completed pediatrics residency at the Children’s Hospital of Philadelphia. She spent two years as a global health corps physician with the Baylor International Pediatric AIDS Initiative in eSwatini before completing her fellowship in Pediatric Infectious Diseases at the Johns Hopkins University School of Medicine. She completed a Master’s degree in epidemiology, focusing on clinical trials and evidence-based synthesis, at the Johns Hopkins Bloomberg School of Public Health. She joined the faculty of the division of pediatric infectious diseases in 2016.

Dr. Salazar-Austin’s research focuses on combining existing and new biomedical interventions in tuberculosis with novel pediatric health care delivery models to improve implementation of TB preventive therapy in TB-exposed children and adolescents with and without HIV worldwide.

...read more

Titles

  • Assistant Professor of Pediatrics

Departments / Divisions

Education

Degrees

  • MD; Harvard Medical School (2008)

Residencies

  • Pediatrics; Children's Hospital of Philadelphia (2011)

Fellowships

  • Pediatric Infectious Diseases; Johns Hopkins University School of Medicine (2016)

Board Certifications

  • American Board of Pediatrics (Pediatric Infectious Diseases) (2017)
  • American Board of Pediatrics (Pediatrics) (2011)

Research & Publications

Clinical Trials

01/01/2020 - 08/30/2022


CHIP-TB Trial (Child Home Initiated Preventive treatment for TB)


Funded by UNITAID and the IMPAACT4TB project, this cluster-randomized trial will compare home-based vs clinic-based evaluation and initiation of TB preventive therapy (3RH or 3HP) in child TB contacts less than 15 years of age in Ethiopia and South Africa. This includes pre and post-trial qualitative assessments and a cost-effectiveness evaluation.


Principle Investigator 


07/01/2019-06/30/2022


Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Infants, Children and Adolescents


IMPAACT 2024 will study the PK and safety of 1HP, or one month of weekly rifapentine and isoniazid for TB prevention. This study will also assess drug interactions with dolutegravir and efavirenz in children living with HIV.


Co-chair

Selected Publications

Nicole Salazar-Austin, Silvia Cohn, Sanjay Lala, Ziyaad Waja, Kelly E Dooley, Christopher J Hoffmann, Richard E Chaisson, Neil Martinson and the TSHEPISO Study Team. Isoniazid Preventive Therapy and Pregnancy Outcomes In HIV-Infected Women in the Tshepiso Cohort, Clinical Infectious Diseases

Nicole Salazar-Austin, Silvia Cohn, Grace Link Barnes, Molefi Tladi, Katlego Motlhaoleng, Catharina Swanepoel, Zarina Motala, Ebrahim Variava, Neil Martinson, Richard E Chaisson. Improving Tuberculosis Preventive Therapy Uptake: A Cluster-randomized Trial of Symptom-based Versus Tuberculin Skin Test-based Screening of Household Tuberculosis Contacts Less Than 5 Years of Age, Clinical Infectious Diseases Volume 70, Issue 8, 15 April 2020, Pages 1725–1732

Nicole Salazar-Austin, Jennifer Hoffmann, Silvia Cohn, Fildah Mashabela, Ziyaad Waja, Sanjay Lala, Christopher Hoffmann, Kelly E Dooley, Richard E Chaisson, Neil Martinson, TSHEPISO Study Team Poor Obstetric and Infant Outcomes in Human Immunodeficiency Virus-Infected Pregnant Women With Tuberculosis in South Africa: The Tshepiso Study, Clinical Infectious Diseases Volume 66, Issue 6, 15 March 2018, Pages 921–929

Is this you? Edit Profile
back to top button